Results from the Titan Study show promise that broadly neutralising antibodies (BNABS) are a component of a future HIV Cure. hivcure.com.au/2023/09/13/bna…

Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection. Virus Eradication sciencedirect.com/science/articl…

In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s4159…

Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation. 🌟 Fully funded doctoral positions for translational projects 🌟 Open for applications until Nov 22 bihealth.org/en/notices/bih…

Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. eviden.cc/3ScIr1C

If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by ECDC and EACS ⏲️ Deadline: 30 November 2023 #StigmaFree

Editorial: “Host Receptor Targeting to Treat #Covid19” by Jesper D. Gunst and Ole Schmeltz Søgaard eviden.cc/3ScIr1C #SARSCov2 #InfectiousDisease Aarhus University Aarhus Uni.hospital Steven Tong Joshua Davis Jason Roberts

The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec! Complete it today or spread the word in your network. 🔄 Available in 38+ languages! 🌍 Survey link: ow.ly/w7vH50QcPWv ECDC

Onto my fave topic - analytical treatment interruptions: where ART is stopped in an #HIVcure study. Viral rebound. Tongcui Ma showed T cell features (pic 1) and Mauro Garcia showed IgG antibodies (pic 2) impacted time to viral rebound. Use as biomarkers for TVR? #CROI2024

How to interpret and how to manage low level viremia? Hearing now from Jesper D. Gunst with important insight from amazing session chair Casper Rokx at #YINGconf24

Vibeke Klastrup presenting metanalysis of ATI studies showing smaller reservoir size and interventions such as #bNAbs are associated with duration of viral control during treatment interruptions. #AIDS2024

Exciting news! Our survey report with ECDC on #HIV #stigma in the #healthcare setting is now available. Huge thanks to everyone who contributed to its success! 👉bit.ly/46kI1uN Don't miss the presentation on Friday by Teymur Noori at #AIDS2024

🚨 We’re hiring! 🚨 Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info: nature.com/naturecareers/…